Ligand-Based CAR-T Cells Targeting EGFR Exhibit Favorable Antitumor Effects Against Gynecologic Malignancies

Area of Science:

• Oncology
• Immunotherapy
• Gynecologic Oncology

Background:

• Epidermal growth factor receptor (EGFR) is overexpressed in gynecologic malignancies.
• Clinical efficacy of current EGFR-targeted therapies for these cancers is not established.

Purpose of the Study:

• To investigate the antitumor effects of ligand-based EGFR-targeted Chimeric Antigen Receptor (CAR)-T cells in gynecologic malignancies.

Main Methods:

• EGFR expression was assessed in patient samples via immunohistochemistry.
• Ligand-based EGFR CAR-T cells were generated using piggyBac-mediated gene transfer.
• Antitumor activity was evaluated through in vitro co-culture assays and in vivo studies using tumor-bearing mice.

Main Results:

• EGFR was detected in 41% of ovarian, 82% of endometrial, and 79% of cervical cancer samples.
• EGFR CAR-T cells significantly suppressed the growth of six EGFR-positive gynecologic cancer cell lines in vitro.
• In vivo, EGFR CAR-T cell treatment led to decreased tumor burden and increased survival in mice.

Conclusions:

• Ligand-based EGFR CAR-T cells demonstrate significant antitumor effects against gynecologic malignancies.
• EGFR CAR-T cell therapy represents a potential new treatment strategy for these cancers.